Abstract
The ubiquitin system controls protein stability and function. F-box proteins form SCF (SKP1-Cullin1-F-box protein)-type ubiquitin (E3) ligases to selectively target their substrates for degradation via the ubiquitin–proteasome pathway. Here, we review F-box proteins associated with cancer development. S-phase kinase-associated protein 2 (SKP2) (also known as FBXL1) is often overexpressed in human cancers, and functions as an oncogenic E3 ligase to degrade tumor suppressor gene products. Moreover, F-box/WD repeat-containing protein 7 (FBXW7) (also known as Fbw7) is often mutated in human cancers and functions as a tumor suppressive E3 ligase targeting oncogenic proteins for degradation. SKP2 is a potential drug target for cancer therapy and FBXW7 is useful in determining patient diagnosis, prognosis, and drug sensitivity. In this review, we also discuss other F-box proteins involved in cancer-associated cellular processes such as cell cycle control, epigenetic regulation, epithelial mesenchymal transition, apoptosis/survival, drug resistance, and DNA-damage responses.
Keywords: β-TrCP, E3 ligase, F-box protein, FBXW7, human cancer, proteasome, SCF complex, SKP2, ubiquitin.
Current Cancer Drug Targets
Title:The SCF-type E3 Ubiquitin Ligases as Cancer Targets
Volume: 16 Issue: 2
Author(s): Kyoko Kitagawa and Masatoshi Kitagawa
Affiliation:
Keywords: β-TrCP, E3 ligase, F-box protein, FBXW7, human cancer, proteasome, SCF complex, SKP2, ubiquitin.
Abstract: The ubiquitin system controls protein stability and function. F-box proteins form SCF (SKP1-Cullin1-F-box protein)-type ubiquitin (E3) ligases to selectively target their substrates for degradation via the ubiquitin–proteasome pathway. Here, we review F-box proteins associated with cancer development. S-phase kinase-associated protein 2 (SKP2) (also known as FBXL1) is often overexpressed in human cancers, and functions as an oncogenic E3 ligase to degrade tumor suppressor gene products. Moreover, F-box/WD repeat-containing protein 7 (FBXW7) (also known as Fbw7) is often mutated in human cancers and functions as a tumor suppressive E3 ligase targeting oncogenic proteins for degradation. SKP2 is a potential drug target for cancer therapy and FBXW7 is useful in determining patient diagnosis, prognosis, and drug sensitivity. In this review, we also discuss other F-box proteins involved in cancer-associated cellular processes such as cell cycle control, epigenetic regulation, epithelial mesenchymal transition, apoptosis/survival, drug resistance, and DNA-damage responses.
Export Options
About this article
Cite this article as:
Kitagawa Kyoko and Kitagawa Masatoshi, The SCF-type E3 Ubiquitin Ligases as Cancer Targets, Current Cancer Drug Targets 2016; 16 (2) . https://dx.doi.org/10.2174/1568009616666151112122231
DOI https://dx.doi.org/10.2174/1568009616666151112122231 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Progress in Immunotherapy of Head and Neck Squamous Cell Carcinoma
Current Molecular Pharmacology E2F1-Mediated Apoptosis as a Target of Cancer Therapy
Current Molecular Pharmacology Gene Electrotransfer to Skin; Review of Existing Literature and Clinical Perspectives
Current Gene Therapy Adenovirus-Based Cancer Gene Therapy
Current Gene Therapy Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design The Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological Malignancies
Current Drug Targets Identifying Biomarkers of Lung Cancer in the Post-Genomic Era
Current Pharmacogenomics Role of Microtubules Network in CYP Genes Expression
Current Drug Metabolism Predictive In Silico Studies of Human 5-hydroxytryptamine Receptor Subtype 2B (5-HT2B) and Valvular Heart Disease
Current Topics in Medicinal Chemistry Recent Advances in Computer-Assisted Structure-Based Identification and Design of Histone Deacetylases Inhibitors
Current Topics in Medicinal Chemistry Attempted Cell Cycle Induction in Post-Mitotic Neurons Occurs in Early and Late Apoptotic Programs Through Rb, E2F1, and Caspase 3
Current Neurovascular Research Cyclin Dependent Kinase 1 Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets The Mouse In Cancer Research Past, Present, Future
Current Genomics Antiproliferative Strategies for the Treatment of Vascular Proliferative Disease
Current Vascular Pharmacology The Cancer Hygiene Hypothesis: From Theory to Therapeutic Helminths
Current Cancer Therapy Reviews Analysis of the Potential for HIV-1 Vpr as an Anti-Cancer Agent
Current HIV Research Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin
Current Cancer Drug Targets Differential Binding Preference of Methylpheophorbide a and Its Diboronated Derivatives to Albumin and Low Density Lipoproteins
Anti-Cancer Agents in Medicinal Chemistry Ca<sup>2+</sup> Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation
Current Vascular Pharmacology